Trials for DARZALEX FASPRO

The main goal of the study was to measure the length of time patients lived without having their multiple myeloma get worse or passing away. 304 patients.

For relapsed or refractory multiple myeloma, after 1 prior therapy, PLEIADES trial evaluated efficacy and safety of DARZALEX FASPRO ® + Rd.

Johnson & Johnson submits applications in the U.S. and EU seeking ...

The applications are supported by data from the ongoing Phase 3 AQUILA study (NCT03301220) of DARZALEX FASPRO® as monotherapy for the treatment ...

DARZALEX FASPRO ® non-inferiority trial vs DARZALEX ® IV

Phase 3, randomized, open-label, non-inferiority, multicenter trial comparing DARZALEX FASPRO monotherapy vs DARZALEX monotherapy in 522 adult patients.

DARZALEX FASPRO®-based quadruplet regimen significantly ...

Study of the first and only subcutaneous quadruplet regimen demonstrates 60.9 percent improvement in minimal residual disease ...

Home Based Daratumumab Administration for Patients with Multiple ...

This phase II trial tests the treatment effect of home based daratumumab administration in treating patients with multiple myeloma. Darzalex Faspro is a ...

FDA approves daratumumab and hyaluronidase-fihj with bortezomib ...

Treatment with Darzalex Faspro-VRd resulted in a reduction in the risk of disease progression or death by 60% compared to VRd alone (HR [95% CI]: ...

Clinical Trials Using Daratumumab and Hyaluronidase-fihj - NCI

This phase III trial compares the effect of usual treatment (lenalidomide) to using daratumumab/rHuPH20 plus the usual treatment after stem cell transplantation ...

J&J Posts Positive Phase III Results for Carvykti and Darzalex ...

J&J linked the addition of Darzalex Faspro to VRd to a 60.9% improvement in minimal residual disease-negativity, causing the study to meet its ...

J&J seeks new FDA approval of Darzalex Faspro myeloma combo

New US approval sought for Darzalex Faspro quadruple therapy · Phase 1b trial enrolling to test continuous low-dose lenalidomide · CEPHEUS ...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for ...

The randomized, phase 2 GRIFFIN study evaluated the efficacy and safety of intravenous daratumumab combined with VRd induction and consolidation therapy and ...

DARZALEX FASPRO - MMY3019 (CEPHEUS) Study

SUMMARY ... CEPHEUS (MMY3019) is a phase 3 study evaluating the efficacy and safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide, and ...

About DARZALEX® & DARZALEX FASPRO® (daratumumab and ...

DARZALEX FASPRO and DARZALEX are prescription medicines used alone or in combination with one or more treatments for adults with a rare form of blood cancer ...

Use of DARZALEX + DARZALEX FASPRO in Smoldering Multiple ...

Summary · AQUILA is a phase 3 study evaluating the safety and efficacy of DARZALEX FASPRO versus active monitoring in patients with high-risk SMM. · CENTAURUS ...

B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II ...

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) ...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

The data were published simultaneously in The New England Journal of Medicine. The PERSEUS study, conducted in collaboration with the European ...

DARZALEX FASPRO® for the Treatment of Light Chain (AL ...

Clinical trials on DARZALEX FASPRO. FDA approval of DARZALEX FASPRO was based on the results of Phase III clinical trial, named ANDROMEDA ...

FDA grants accelerated approval to Darzalex Faspro for amyloidosis

On January 15, 2021, the Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, ...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj ...

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly ...

Daratumumab Myeloma Trials - SparkCures

Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the ...